Egyesült Államok - angol - NLM (National Library of Medicine)

rebel distributors corp - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - hypertension      losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology, pharmacodynamics and clinical effects, and dosage and administration). hypertensive patients with left ventricular hypertrophy      losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race, clinical pharmacology, pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration). losartan potassium and hydrochlorothiazide tablets are contraindicated in patie

Egyesült Államok - angol - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - when used in pregnancy during the second and third trimesters, drugs that act directly on the renin­angiotensin system can cause injury and even death to the developing fetus. when pregnancy is detected, losartan potassium and hydrochlorothiazide should be discontinued as soon as possible. see warnings: fetal/neonatal morbidity and mortality . losartan potassium and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology: pharmacodynamics and clinical effects, and dosage and administration ). losartan potassium and hydrochlorothiazide tablets usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply t

Egyesült Államok - angol - NLM (National Library of Medicine)

stat rx usa llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - hypertension      losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology , pharmacodynamics and clinical effects, and dosage and administration ). hypertensive patients with left ventricular hypertrophy      losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients (see precautions , race, clinical pharmacology , pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration ). losartan potassium and hydrochlorothiazide tablets are contraindi

Egyesült Államok - angol - NLM (National Library of Medicine)

dispensing solutions, inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 100 mg - hypertension      losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology, pharmacodynamics and clinical effects, and dosage and administration). hypertensive patients with left ventricular hypertrophy      losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race, clinical pharmacology, pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration). losartan potassium and hydrochlorothiazide tablets are contraindicat

Egyesült Államok - angol - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive

Egyesült Államok - angol - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 100 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive

Egyesült Államok - angol - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race    and  clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race ). losartan potassium tablets usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium tablets usp reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see clinical pharmac

Egyesült Államok - angol - NLM (National Library of Medicine)

legacy pharmaceutical packaging, llc - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients ( see precautions , race and clinical pharmacology , pharmacodynamics and clinical effects, reduction in the risk of stroke , race ). losartan potassium tablets usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥ 300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium tablets usp reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see clinical pharmaco

Egyesült Államok - angol - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 50 mg - losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihyp

Egyesült Államok - angol - NLM (National Library of Medicine)

golden state medical supply, inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets, usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see  precautions, race  and clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race .) losartan potassium tablets, usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium tablets, usp reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (nee